Evaluation of the efficacy and safety of epidural steroid injection using a nonparticulate steroid, dexamethasone or betamethasone: a double-blind, randomized, crossover, clinical trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Geun Young | - |
dc.contributor.author | Lee, Joon Woo | - |
dc.contributor.author | Lee, Eugene | - |
dc.contributor.author | Yeom, Jin S. | - |
dc.contributor.author | Kim, Ki-Jeong | - |
dc.contributor.author | Shin, Hyung-Ik | - |
dc.contributor.author | Kang, Heung Sik | - |
dc.date.accessioned | 2024-05-14T00:31:00Z | - |
dc.date.available | 2024-05-14T00:31:00Z | - |
dc.date.issued | 2022-07 | - |
dc.identifier.issn | 2005-9159 | - |
dc.identifier.issn | 2093-0569 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/73654 | - |
dc.description.abstract | Background: The U.S. Food and Drug Administration has prohibited epidural steroid injection (ESI) with particulate steroids. Thus, this study aimed to compare the efficacy and safety of ESI with two nonparticulate steroids, dexamethasone and betamethasone.Methods: The eligible patients (n = 600) who received ESI (0 week) with dexamethasone (ESI-dexa) or betamethasone (ESI-beta) had follow-up visits at 2, 4, and 8 weeks with a phone interview at 12 weeks. The primary endpoint was the proportion of effective responders without pain or who were much improved at 2 weeks. The secondary endpoints were the proportion of crossover injections at 2 weeks; changes in the visual analog scale (VAS) and disability index scores at 2, 4, and 8 weeks; the number of additional ESIs in 12 weeks; the number of participants having spinal surgery, as well as the incidence of adverse events over the 12 weeks.Results: The proportion of effective responders at 2 weeks was not different between ESI-beta (72/216, 33.3%) and ESI-dexa (63/200, 31.5%; P = 0.670). Adverse events were more common with ESI-dexa (40/200, 20.0%) than with ESI-beta (24/216, 11.1%; P = 0.012). VAS scores decreased more with ESI-beta than with ESI-dexa at 2 weeks (difference, 0.35; P = 0.023) and 4 weeks (difference, 0.42; P = 0.011). The disability score improved significantly more with ESI-beta compared with ESI-dexa at 2 weeks (difference, 3.37; P = 0.009), 4 weeks (difference, 4.01; P = 0.002), and 8 weeks (difference, 3.54; P = 0.007).Conclusions: Betamethasone would be more appropriate for ESI. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 대한통증학회 | - |
dc.title | Evaluation of the efficacy and safety of epidural steroid injection using a nonparticulate steroid, dexamethasone or betamethasone: a double-blind, randomized, crossover, clinical trial | - |
dc.type | Article | - |
dc.identifier.doi | 10.3344/kjp.2022.35.3.336 | - |
dc.identifier.bibliographicCitation | The Korean Journal of Pain, v.35, no.3, pp 336 - 344 | - |
dc.identifier.kciid | ART002855543 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000945733500001 | - |
dc.identifier.scopusid | 2-s2.0-85135083415 | - |
dc.citation.endPage | 344 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 336 | - |
dc.citation.title | The Korean Journal of Pain | - |
dc.citation.volume | 35 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Betamethasone | - |
dc.subject.keywordAuthor | Comparative Study | - |
dc.subject.keywordAuthor | Dexamethasone | - |
dc.subject.keywordAuthor | Incidence | - |
dc.subject.keywordAuthor | Injections | - |
dc.subject.keywordAuthor | Epidural | - |
dc.subject.keywordAuthor | Pain | - |
dc.subject.keywordAuthor | Spine | - |
dc.subject.keywordAuthor | Steroids | - |
dc.subject.keywordPlus | CORTICOSTEROID PREPARATIONS | - |
dc.subject.keywordPlus | PARTICULATE STEROIDS | - |
dc.subject.keywordPlus | PAIN | - |
dc.subject.keywordPlus | TRIAMCINOLONE | - |
dc.subject.keywordPlus | REDUCTION | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.